Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Baxdrostat · Baxfendy, CIN-107

Small molecule · Inhibitor of aldosterone synthase (CYP11B2) · developed by Astrazeneca

Approved FDA, May 2026
AZN Developer

What is Baxdrostat?

Baxdrostat is an oral inhibitor of aldosterone synthase, the enzyme that produces aldosterone, with higher potency and selectivity for it than for 11β-hydroxylase, the final enzyme in cortisol synthesis. By lowering aldosterone, it reduces sodium and water retention and blood pressure. It is studied in hypertension, including uncontrolled and resistant hypertension, and in hypertension with chronic kidney disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Baxfendy, CIN-107, RO-6836191
Drug type
Small molecule
Targets
aldosterone synthase (CYP11B2), 11β-hydroxylase (CYP11B1) (secondary target)
Mechanism
Inhibitor of aldosterone synthase (CYP11B2)
Pathways
aldosterone synthesis, renal sodium and water retention
Therapy area
Cardiovascular, Renal & urology
Developer
Astrazeneca Ab (AZN)
FDA status
Approved as Baxfendy (May 15, 2026), NDA219878 · FDA label
UNII
NF3P9Z8J5Y

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 7, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Chronic Kidney Disease and HypertensionResistant HypertensionUncontrolled Hypertension

More from Astrazeneca

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Baxdrostat

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.